1. Introduction
===============

Osteoporotic vertebral compression fractures (OVCFs) constitute an age-related health problem that affects approximately 200 million people worldwide.^\[[@R1]\]^ In addition, they are the most common osteoporotic fractures, occurring in approximately 20% individuals older than 70 years.^\[[@R2]\]^ Patients with severe OVCFs suffer from acute pain, disability, and even mortality.^\[[@R3]\]^ Thus, OVCFs represent a serious health concern in old people, particularly the elderly.

Currently, various treatments are performed with the goal of reducing pain, stabilizing the vertebrate, and restoring mobility.^\[[@R4]--[@R6]\]^ Conservative treatment (CT), which includes rest, external fixation, anti-inflammatory drugs, and analgesics, is effective only for a small portion of patients with OVCFs,^\[[@R7]\]^ but it is associated with undesirable adverse effects and often fails in preventing kyphotic deformity.^\[[@R8],[@R9]\]^ Conversely, vertebroplasty (VP) and kyphoplasty (KP) are minimally invasive surgical treatments for OVCFs that can relieve pain quickly, improve mobility, and restore vertebral height.^\[[@R10],[@R11]\]^

Numerous pairwise meta-analyses have been performed for head-to-head comparisons of KP with VP with respect to the aspects of complications,^\[[@R12]\]^ pain reduction,^\[[@R13]\]^ and disability.^\[[@R13]--[@R15]\]^ In addition, a more comprehensive meta-regression analysis has been conducted,^\[[@R16]\]^ but an integrated and credible conclusion remains elusive because CT has not always been the control treatment and non-randomized trials have been included. A Bayesian network meta-analysis (NMA) is superior to traditional analyses when comparing multiple treatments because it combines direct and indirect comparisons and provides a posterior probability distribution for distinguishing subtle differences among treatments.^\[[@R17],[@R18]\]^ To the best of our knowledge, there has only been 1 NMA focusing on the efficacy and tolerability of the 3 main treatments (KP, VP, and CT) for OVCFs.^\[[@R19]\]^ However, this only included 5 randomized controlled trials (RCTs) and restricted outcomes to visual analog scale (VAS) results, all-cause discontinuation, and new fractures.

In this study, we performed a Bayesian NMA with larger RCTs that included more outcome measures. Our aim was to achieve a more integrated and comprehensive comparison of the 3 treatments for OVCFs.

2. Methods
==========

2.1. Data acquisition and search strategy
-----------------------------------------

PubMed and Embase databases were searched until December 31, 2016, using the following keywords: vertebroplasty, kyphoplasty, compression, fracture, fractures, osteoporotic, and osteoporosis. Reference lists of relevant articles were also searched manually to identify additional eligible studies. Because this was a meta-analysis of study data, ethical approval was not necessary.

2.2. Selection criteria
-----------------------

Studies were included if they were RCTs, published in full in English, included patients with OVCFs, and had a control group that underwent CT, and an intervention group that underwent VP or KP. In addition, studies were required to contain at least of one of the following outcome measures: pain relief (VAS; scores ranging from 0 to 10, with 10 indicating the worst pain imaginable),^\[[@R20]\]^ daily function \[Roland--Morris Disability Questionnaire (RDQ); scores ranging from 0 to 24, with a higher score indicating worse physical functioning\],^\[[@R21]\]^ quality of life \[European Quality of Life-5 Dimensions (EQ-5D); scores ranging from 0 to 1, with 1 indicating perfect health\],^\[[@R22]\]^ and new fractures. Nonrandomized trials, reviews, reports, comments, and letters were excluded.

2.3. Data extraction and quality assessment
-------------------------------------------

Two reviewers extracted data from eligible literatures independently. This included the following: name of the first author, year of publication, location of the study, year of the study, type of intervention, demographic characteristics (number, sex, and age), duration of follow-up, and outcomes. The quality of eligible trials was assessed using following the Cochrane Handbook for Systematic Reviews of Interventions^\[[@R23]\]^ and Jadad score. Any disagreement was settled by group discussion with a third investigator.

2.4. Statistical analysis
-------------------------

For the dichotomous outcome of new fractures, results were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). For continuous outcomes of VAS, RDQ, and EQ-5D, the mean difference (MD) was used to evaluate effects of the 3 treatments. If the 95% CI included 1 for OR or zero for MD, the results were not considered to be significantly different.

The pairwise meta-analysis was performed using R software version 3.12 (R Foundation for Statistical Computing, Beijing1, China, meta package). The potential heterogeneity across the studies was examined using the Q statistic^\[[@R24]\]^ and *I*^2^ index. A random-effects model was used to pool the effect size if there was significant heterogeneity (*P* \< .05 or *I*^2^ \> 50%); otherwise, a fixed-effects model was adopted.^\[[@R25]\]^

To incorporate indirect comparisons, NMA was conducted using the Aggregate Data Drug Information System (ADDIS) software (Version 1.16.5, Erasmus University, The Netherlands). ADDIS is a nonprogramming software that can assess and process data using Markov chain Monte Carlo methods in a Bayesian framework.^\[[@R26],[@R27]\]^ The parameters in the ADDIS software were set as follows: number of chains = 4, tuning iterations = 20,000, simulation iterations = 50,000, thinning interval = 10, inference samples = 10,000, and variance scaling factor = 2.5. A random-effects model was used to pool the effect size. A node-splitting analysis was applied in the ADDIS software for evaluating any inconsistencies within NMA, and a consistency model was adopted when a *P*-value \> .05 was observed during the comparison between direct and indirect evidence, and an inconsistency model was chosen otherwise.^\[[@R28]\]^ The convergence of iterative simulation was interpreted by the potential scale reduction factor (PSRF) calculated by the Brooks--Gelman--Rubin method.^\[[@R29]\]^ The rank probability for each treatment was also estimated graphically with the ADDIS software. Finally, Egger\'s test was used to verify the potential for publication bias.

3. Results
==========

3.1. Eligible studies
---------------------

The flow diagram for the literature selection is shown in Fig. [1](#F1){ref-type="fig"}. The search strategy originally yielded 2775 articles (1324 articles from the PubMed database and 1451 articles from the Embase database) and 1614 articles remained after removing duplicates. Another 1424 irrelevant articles were then removed after screening study titles and abstracts. Finally, 174 articles (53 reviews, 21 letters to editors, 31 case series or reports, 22 non-RCTs, 16 articles with duplicated populations, and 31 articles with inadequate outcomes) were excluded after reviewing the full text of the remaining 190 articles. Thus, 16 eligible studies were included in NMA.^\[[@R30]--[@R45]\]^

![Flow chart of study selection.](medi-96-e7328-g001){#F1}

3.2. Study characteristics and quality assessment
-------------------------------------------------

Characteristics of eligible studies are shown in Table [1](#T1){ref-type="table"}. The number of patients who underwent KP, VP, and CT was 478, 816, and 752, respectively. The average age of patients ranged from 63 to 81 years, and the sex distribution was comparable between intervention and control groups. Follow-up durations lasted from 2 weeks to 3 years. Among the 16 RCTs, 11 compared the effect of VP with CT, 2 compared the effect of KP with CT, and 3 compared the effect of KP and VP. The Jadad scores were between 3 and 5, suggesting high quality of the included studies.

###### 

Characteristics of the identified studies.

![](medi-96-e7328-g002)

The bias of the eligible studies is summarized in Fig. [2](#F2){ref-type="fig"}A. Only 2 of the 16 studies had a low risk of performance bias with respect to the blinding of participants and personnel,^\[[@R41],[@R46]\]^ with the remaining studies having unclear risk. Two studies had high risk of reporting bias^\[[@R40],[@R42]\]^ and 3 studies had a high risk of other bias.^\[[@R37],[@R45],[@R47]\]^ As illustrated in Fig. [2](#F2){ref-type="fig"}B, the quality of life of patients in most of the selected studies was rated as good.

![Results of quality assessment. (A) Summary of the risk of bias. (B) Graph of the risk of bias.](medi-96-e7328-g003){#F2}

3.3. Meta-analyses
------------------

Among the 4 outcomes, a closed triangle circular was shown for new fractures and EQ-5D only. A node-splitting analysis was performed to check for inconsistencies in these 2 outcomes (Table [2](#T2){ref-type="table"}) and showed that *P*-values were all \> .5, indicating a lack of significant inconsistency. In addition, PSRF for the 5 outcomes was between 1.00 and 1.01, suggesting a complete convergence and good iteration simulation. Given these results, a consistency model was adopted for NMA.

###### 

The node-splitting analysis for new fractures and EQ-5D.
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3.4. Pain
---------

Table [3](#T3){ref-type="table"} summarizes the results of pairwise meta-analysis and NMA based on the VAS score for pain. Both NMA (MD, −1.12; 95% CI:−1.80, −0.51) and pairwise meta-analysis (MD, −1.13; 95% CI:−1.70, −0.56) showed that patients who underwent VP had a significantly greater pain relief than those who underwent CT.

###### 

Multiple treatments comparison regarding VAS.
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3.5. Quality of life
--------------------

As shown in Table [4](#T4){ref-type="table"}, NMA (MD, 0.07; 95% CI: 0.00, 0.11) and pairwise meta-analysis (MD, 0.05; 95% CI: 0.02, 0.08) indicated that there was a significant improvement in quality of life among patients who underwent VP compared with those who underwent CT.

###### 

Multiple treatments comparison regarding EQ-5D.
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3.6. Functional outcome
-----------------------

NMA (MD, −2.51; 95% CI:−5.37, −0.28) and pairwise meta-analysis (MD, −2.50; 95% CI: −3.40, −1.60) suggested that VP was significantly associated with a greater beneficial effect on daily function than CT (Table [5](#T5){ref-type="table"}).

###### 

Multiple treatments comparison regarding RDQ.
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3.7. New fractures
------------------

According to the pooled estimates (Table [6](#T6){ref-type="table"}) measured by pairwise meta-analysis and NMA, there was no significant difference among the 3 treatments in the incidence of new fractures.

###### 

Multiple treatments comparison regarding new fractures.
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3.8. Rank probability
---------------------

Figure [3](#F3){ref-type="fig"}A--C summarizes rank probabilities of the 3 treatments with respect to VAS, RDQ, and incidence of new fractures, respectively, with rank 1 indicating the worst result. Figure [3](#F3){ref-type="fig"}D presents the rank probability for EQ-5D, with rank 1 being the best result. KP treatment had the most beneficial effect on daily function, quality of life, and incidence of new fractures, followed by VP and CT. In addition, VP was the most efficacious treatment for pain relief, followed by KP and CT.

![Rank probabilities for conservative treatment, kyphoplasty, and vertebroplasty: (A) visual analog scale; (B) Roland--Morris Disability Questionnaire; (C) new fractures; (D) European Quality of Life-5 Dimensions.](medi-96-e7328-g009){#F3}

3.9. Publication bias
---------------------

No publication bias was observed among the eligible studies (Table S1).

4. Discussion
=============

In this study, we performed NMA for evaluating the efficacy (in terms of VAS, RDQ, and EQ-5D) and safety (in terms of new fractures) of 3 treatments for patients with OVCFs based on data from 16 RCTs. NMA and pairwise meta-analysis indicated that VP significantly decreased pain, improved the quality of life, and strengthened the daily function compared with CT. Moreover, no significant difference was observed in the incidence of new fractures among the 3 treatments. When aiming to alleviate pain, VP was more effective than KP; however, KP was more effective than VP when aiming to improve daily function and quality of life and to decrease the incidence of new fractures. In both cases, CT was the least effective.

Our results indicated that greater pain relief was achieved in patients with OVCFs who underwent VP than in those who underwent CT. Several pairwise meta-analyses provided robust support for this conclusion.^\[[@R48]--[@R50]\]^ In addition, our findings suggested that there was no significant difference between VP and KP in pain reduction. Although a number of meta-analyses have compared the effects of these 2 treatments on pain relief,^\[[@R13],[@R51],[@R52]\]^ there are controversies in the results probably because of the inclusion of nonrandomized controlled trials. Consistent with our analysis, in NMA of 5 RCTs, Chen et al^\[[@R19]\]^ concluded that there was no significant difference between VP and KP with respect to VAS. Also, consistent with the analysis performed by Chen et al,^\[[@R19]\]^ we showed that VP was the most efficacious therapy for relieving acute pain, followed by KP and CT.

All 3 investigated treatments had comparable effects on the incidence of new fractures in this NMA. Meta-analyses showed that KP and VP were associated with similar risks of new fractures,^\[[@R13],[@R14],[@R51]\]^ but that there was no significant difference in risk of new fractures between VP and CT.^\[[@R48],[@R53]\]^ Of the few studies that directly compared KP and CT in terms of the incidence of new fractures, NMA reported that there was no significant difference between KP, VP, and CT, but that there was a subtle difference after ranking.^\[[@R19]\]^ Inconsistent with this result, we were able to rank KP first in our investigation. The inclusion of fewer RCTs may account for this disagreement.

As shown in our analysis, patients who underwent VP had significantly improved the daily function and quality of life compared with those who underwent CT, whereas no significant difference was found between VP and KP for these measures. Several investigations provided support for the superiority of VP over CT on recovery in function and improvement in the quality of life.^\[[@R48],[@R53]\]^ Xing et al^\[[@R14]\]^ detected no significant difference between KP and VP in the improvement of short- and long-term function. However, conflicting result was shown in a meta-analysis based on the cohort study.^\[[@R13]\]^ Limited RCT data might be the main obstacle for providing a definitive conclusion on the comparison of the effect of KP with that of VP on daily function. Furthermore, few studies have compared the effects of KP and VP on quality of life. Our findings provided additional evidence on relative merits of VP and KP on daily function and quality of life, with the probability analysis suggesting that KP might be superior to VP.

Our results should be interpreted cautiously because of the limitations of the study. First, no subgroup meta-analysis was performed because of the lack of conformity in the duration of follow-up and inadequacy of raw data. Second, no closed triangle circle was shown for VAS and RDQ outcomes, and there were limited RCTs for certain pairwise meta-analyses (e.g., only 1 RCT compared the effectiveness of KP and CT with VAS). This could decrease confidence in our conclusions. Third, the effect size was only pooled using a random-effects model, which was a restriction of the ADDIS software, and this might have produced conservative conclusions. Finally, heterogeneity such as caused by the follow-up times (from 2 weeks in 1 study to years in some), performance bias, and reporting bias might limit the reliability of our conclusions.

5. Conclusion
=============

In conclusion, VP was the best procedure for relieving pain, whereas KP, which is associated with higher costs, was associated with the lowest incidence of new fractures and best improvement in daily function and quality of life. Our findings provide evidence-based support for applying these procedures in the treatment of OVCFs. However, because of the limitation of the present study, such as heterogeneity caused by the follow-up times, larger scale RCTs of higher quality are urgently needed to confirm these conclusions.
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